Inc. raised its position in Regeneron Pharmaceuticals by 3.4% in the first quarter. (NASDAQ:REGN) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. Currently, 316.33 million total shares are owned by the public and among those 316.25 million shares have been available to trade. Two research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company. Rockefeller Financial Services Inc. boosted its position in shares of Regeneron Pharmaceuticals by 13.0% in the first quarter. Concert Wealth Management Inc. now owns 723 shares of the biopharmaceutical company’s stock valued at $269,000 after buying an additional 3 shares during the period. Sumitomo Mitsui Trust has 0.13% invested in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) for 216,002 shares. Oppenheimer & Co. Inc. now owns 5,808 shares of the biopharmaceutical company’s stock valued at $2,251,000 after buying an additional 189 shares during the last quarter. Vanguard Group Inc. boosted its stake in Regeneron Pharmaceuticals by 4.1% in the first quarter. BB&T Corp boosted its position in shares of Regeneron Pharmaceuticals by 51.5% in the first quarter. Wall Street is only getting more bullish on the stock, with 10 of analysts who cover REI having a buy-equivalent rating. CIBC World Markets Inc. raised its position in Regeneron Pharmaceuticals by 2,190.6% in the first quarter. Princeton Capital Management Inc. now owns 2,496 shares of the biopharmaceutical company’s stock valued at $967,000 after buying an additional 157 shares during the last quarter. Ring Energy, Inc. (REI) has made its way to a 12-month gain of 18.01%. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/08/29/neuberger-berman-group-llc-decreases-stake-in-regeneron-pharmaceuticals-inc-regn.html. The day began at US$483.92 but the price moved to US$477.78 at one point during the trading and finally capitulating to a session high of US$486.35. The company also updated its non-GAAP unreimbursed R&D expenses to $925.0 million-$965.0 million compared to its prior estimate of $950.0 million-$1.0 billion. Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has risen 17.40% since August 29, 2016 and is uptrending. The biopharmaceutical company reported $4.17 earnings per share for the quarter, topping analysts’ consensus estimates of $2.67 by $1.50. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. Revenue during the quarter was $1.47 billion, representing 21% growth from $1.21 billion in year-ago quarter. Regeneron Pharmaceuticals’s revenue for the quarter was up 21.2% on a year-over-year basis. On average, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post $14.85 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This story was reported by Week Herald and is the property of of Week Herald. If you are reading this story on another domain, it was illegally copied and republished in violation of United States & worldwide copyright laws. $482,550 worth of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) shares were sold by GOLDSTEIN JOSEPH L.
REGN has been the subject of several recent research reports. Jefferies maintained it with “Hold” rating and $119 target in Thursday, August 4 report. Piper Jaffray Companies restated an “overweight” rating and set a $557.00 target price on shares of Regeneron Pharmaceuticals in a research report on Tuesday, August 1st. (The) reiterated a “neutral” rating and issued a $472.00 price objective (up from $469.00) on shares of Regeneron Pharmaceuticals in a research report on Wednesday, August 9th. Analysts have issued an “outperform” recommendation and a $605.00 price objective on the shares. UBS AG set a $489.00 price objective on Regeneron Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, May 5th. Regeneron Pharmaceuticals, Inc. has 8 buy ratings, 12 holds and 1 sells even after the stock tumbled -11.84% from its high of $543.55 to a $52.15 billion market value through last close. Regeneron Pharmaceuticals has an average rating of “Hold” and an average target price of $495.59.
In associated news, large stockholder Sanofi bought 136,050 stocks of Regeneron Pharmaceuticals shares in a trade that took place on Fri, Jun 2nd. Shares were disposed in a price range of $532.55, amounting to $4,423,360.30. after the sale, the EVP has an ownership of 43,950 stocks in the company, assessed at roughly $23,405,572.50. executives unloaded 131,790 stocks of company shares valued $62,940,303 in the previous ninety days. National Pension Service now owns 66,518 shares of the biopharmaceutical company’s stock valued at $33,920,000 after buying an additional 6,481 shares during the last quarter. The disclosure for this purchase can be found here.
Regeneron Pharmaceuticals, Inc.is a biopharmaceutical firm that discovers, invents, develops, makes and commercializes medicines for the treatment of serious medical conditions.